aTyr Pharma, Inc. (ATYR)

Market Cap	275.46M
Revenue (ttm)	235,000
Net Income (ttm)	-64.02M
Shares Out	88.86M
EPS (ttm)	-0.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	801,734
Open	3.030
Previous Close	3.020
Day's Range	3.030 - 3.140
52-Week Range	1.420 - 4.660
Beta	0.96
Analysts	Strong Buy
Price Target	18.60 (+498.07%)
Earnings Date	May 1, 2025

About ATYR

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel functions of tRNA synthetases in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of SSc-ILD and other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: ATYR
• Website: https://www.atyrpharma.com

Financial Performance

In 2024, aTyr Pharma's revenue was $235,000, a decrease of -33.43% compared to the previous year's $353,000. Losses were -$64.02 million, 27.1% more than in 2023.

Financial numbers in USD

Analyst Forecast

According to 6 analysts, the average rating for ATYR stock is "Strong Buy." The 12-month stock price forecast is $18.6, which is an increase of 498.07% from the latest price.

Price Target

$18.6

(498.07% upside)

Analyst Consensus: Strong Buy